Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLL17 trial of ibrutinib versus venetoclax-based fixed-duration regimens in previously untreated CLL
NL-OMON52308Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Mar 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Continuous ibrutinib monotherapy, Fixed-duration venetoclax + obinutuzumab and Fixed-duration ibrutinib + venetoclax (3 arms). Primary endpoint: Progression-free survival. Started Mar 2021; status: recruiting.
02
Drugs
ibrutinibvenetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON52308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52308.